Suthar Krishna H, Kesireddy Meghana, Sides Mark, Correa Amit, Ukudeyva Aijan, Venkatesan Rohit
Department of Internal Medicine, University of Texas Medical Branch, USA.
Department of Internal Medicine, Division of Hematology and Medical Oncology, University of Texas Medical Branch, USA.
Case Rep Oncol Med. 2020 Feb 14;2020:7948538. doi: 10.1155/2020/7948538. eCollection 2020.
Squamous cell carcinoma (SCC) of the urethra is a rare malignancy, comprising less than 1% of all malignancies. The annual age-adjusted incidence of urethral SCC is 4.3 per million in men and 1.5 per million in women. Due to the rarity of the disease, there are a limited number of prospective randomized controlled trials to evaluate the optimal management of locally advanced urethral SCC. Here, we present the case of a 47-year-old man with stage IIIB urethral squamous cell cancer that showed complete clinical and pathologic response to neoadjuvant chemoradiation with only 5-flurouracil after incomplete response to traditional chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP).
尿道鳞状细胞癌(SCC)是一种罕见的恶性肿瘤,占所有恶性肿瘤的比例不到1%。经年龄调整后的尿道SCC年发病率,男性为每百万人口4.3例,女性为每百万人口1.5例。由于该疾病罕见,用于评估局部晚期尿道SCC最佳治疗方案的前瞻性随机对照试验数量有限。在此,我们报告一例47岁患有IIIB期尿道鳞状细胞癌的男性病例,该患者在对紫杉醇、异环磷酰胺和顺铂(TIP)传统化疗反应不完全后,对仅使用5-氟尿嘧啶的新辅助放化疗表现出完全的临床和病理反应。